HemaSphere (Apr 2022)
P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL
- MA Dimopoulos,
- A Oriol,
- H Nahi,
- J San-Miguel,
- NJ Bahlis,
- SZ Usmani,
- N Rabin,
- RZ Orlowski,
- K Suzuki,
- T Plesner,
- SS Yoon,
- D Ben Yehuda,
- PG Richardson,
- H Goldschmidt,
- D Reece,
- T Ahmadi,
- X Qin,
- W Garvin Mayo,
- X Gai,
- J Carey,
- R Carson,
- P Moreau
Affiliations
- MA Dimopoulos
- 1 Athens, Greece
- A Oriol
- 2 Barcelona, Spain
- H Nahi
- 3 Stockholm, Sweden
- J San-Miguel
- 4 Pamplona, Spain
- NJ Bahlis
- 5 Calgary, AB, Canada
- SZ Usmani
- 6 New York, NY, USA
- N Rabin
- 7 London, United Kingdom
- RZ Orlowski
- 8 Houston, TX, USA
- K Suzuki
- 9 Tokyo, Japan
- T Plesner
- 10 Vejle, Denmark
- SS Yoon
- 11 Seoul, South Korea
- D Ben Yehuda
- 12 Jerusalem, Israel
- PG Richardson
- 13 Boston, MA, USA
- H Goldschmidt
- 14 Heidelberg, Germany
- D Reece
- 15 Toronto, Canada
- T Ahmadi
- 16 Plainsboro, NJ, USA
- X Qin
- 17 Spring House, PA, USA
- W Garvin Mayo
- 18 Raritan, NJ, USA
- X Gai
- 19 Beijing, China
- J Carey
- 17 Spring House, PA, USA
- R Carson
- 17 Spring House, PA, USA
- P Moreau
- 20 Nantes, France
- DOI
- https://doi.org/10.1097/01.HS9.0000829592.26407.09
- Journal volume & issue
-
Vol. 6
pp. 13 – 13
Abstract
No abstracts available.